Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Amortization of Deferred Charges (2018 - 2022)

Historic Amortization of Deferred Charges for Iterum Therapeutics (ITRM) over the last 5 years, with Q4 2022 value amounting to $590000.0.

  • Iterum Therapeutics' Amortization of Deferred Charges rose 2798.26% to $590000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $2.3 million, marking a year-over-year decrease of 4293.39%. This contributed to the annual value of $2.3 million for FY2024, which is 218.04% down from last year.
  • Latest data reveals that Iterum Therapeutics reported Amortization of Deferred Charges of $590000.0 as of Q4 2022, which was up 2798.26% from $591000.0 recorded in Q3 2022.
  • Over the past 5 years, Iterum Therapeutics' Amortization of Deferred Charges peaked at $3.1 million during Q4 2020, and registered a low of $36000.0 during Q3 2018.
  • Over the past 5 years, Iterum Therapeutics' median Amortization of Deferred Charges value was $587500.0 (recorded in 2022), while the average stood at $997111.1.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first surged by 421388.89% in 2020, then crashed by 8518.16% in 2021.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Amortization of Deferred Charges stood at $186000.0 in 2018, then plummeted by 36.02% to $119000.0 in 2019, then surged by 2514.29% to $3.1 million in 2020, then tumbled by 85.18% to $461000.0 in 2021, then grew by 27.98% to $590000.0 in 2022.
  • Its Amortization of Deferred Charges was $590000.0 in Q4 2022, compared to $591000.0 in Q3 2022 and $585000.0 in Q2 2022.